A Lecture with Bo Rueda Ph.D., July 21, 2025

Dr. Bo Rueda is the Director of the Vincent Center for Reproductive Biology at Massachusetts General Hospital and an Associate Professor at Harvard Medical School. His research focuses on the molecular mechanisms of gynecologic tumors, using advanced xenograft models to develop and test novel cancer therapies.

“Stem-like properties are transferred between ovarian tumor cells via extracellular vesicles facilitating epigenetic changes promoting drug resistance. ”

You are Invited to Attend Our Precision Medicine Seminar Series at the School of Medicine and Public Health, University of Wisconsin Health Sciences Learning Center. July 21, 2025

Recent Publications

Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time.Salas-Benito D, Birocchi F, Park S, Ho CE, Armstrong A, Parker AL, Bouffard AA, Frank JA, Kim E, Kienka T, Graham K, Kelly C, Goncalves S, Leick MB, Escobar G, Rueda B, Berger TR, Maus MV MD,.

J Immunother Cancer. 2025 Sep 9;13(9):e012822. doi: 10.1136/jitc-2025-012822. PMID: 40930746 

ABL1-mediated tyrosine phosphorylation of SYCP2 contributes to transcription-coupled homologous recombination and platinum resistance in ovarian cancer.

Gao B, Wang X, Long M, Zhang F, Wang Y, Kumar R, Veillard I, Rueda BR, Yeku O, Lan L.

NAR Cancer. 2025 Sep 3;7(3):zcaf031. doi: 10.1093/narcan/zcaf031. eCollection 2025 Sep. PMID: 40918650